(Q43642775)

25 November 2017

title

Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan (English)

1 reference

pneumococcal conjugate vaccine

25 November 2017

1 reference

1 reference

Shu-ling Hoshi

1

1 reference

25 November 2017

Masahide Kondo

series ordinal

2

1 reference

25 November 2017

Ichiro Okubo

series ordinal

3

1 reference

25 November 2017

language of work or name

English

0 references

publication date

13 April 2013

1 reference

25 November 2017

1 reference

25 November 2017

volume

31

1 reference

25 November 2017

issue

25

1 reference

25 November 2017

page(s)

2762-2771

1 reference

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease in Japan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

Developing guidance for budget impact analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

Economic evaluation of vaccination programme of 7-valent pneumococcal conjugate vaccine to the birth cohort in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

Incidence of childhood pneumonia and serotype and sequence-type distribution in Streptococcus pneumoniae isolates in Japan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

Pneumococcal conjugate vaccines for preventing otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

Serotype distribution and penicillin resistance of Streptococcus pneumoniae isolates from middle ear fluids of pediatric patients with acute otitis media in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

Effect of pneumococcal conjugate vaccine on pneumococcal meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.052

10.1016/J.VACCINE.2013.03.052

7 January 2021

Identifiers

DOI

1 reference

25 November 2017

1 reference